Zachary Kozick1, Ammar Hashmi2, James Dove3, Marie Hunsinger4, Tania Arora5, Jeffrey Wild6, Mohsen Shabahang7, Joseph Blansfield8. 1. Department of General Surgery, Geisinger Medical Center, United States. Electronic address: zjk001@bucknell.edu. 2. Department of General Surgery, Geisinger Medical Center, United States. Electronic address: AHASHMI@geisinger.edu. 3. Department of General Surgery, Geisinger Medical Center, United States. Electronic address: jtdove@geisinger.edu. 4. Department of General Surgery, Geisinger Medical Center, United States. Electronic address: mahunsinger@geisinger.edu. 5. Department of General Surgery, Geisinger Medical Center, United States. Electronic address: tkarora@geisinger.edu. 6. Department of General Surgery, Geisinger Medical Center, United States. Electronic address: jlwild@geisinger.edu. 7. Department of General Surgery, Geisinger Medical Center, United States. Electronic address: mmshabahang@geisinger.edu. 8. Department of General Surgery, Geisinger Medical Center, United States. Electronic address: jblansfield1@geisinger.edu.
Abstract
BACKGROUND: Oncotype DX (ODX) is a multi-gene tumor assay for breast cancer patients. Our objective is to assess whether eligible ODX patients received the test and whether recommendations were followed based on respective risk. METHODS: We retrospectively analyzed testing in patients deemed eligible for ODX using the National Cancer Data Base. RESULTS: A total of 158,235 patients met ODX eligibility criteria. Sixty-four percent of eligible patients did not receive the test. Non-testing rose with age. White patients were more likely to be tested (56%) versus black patients (46%, p < 0.0001). Testing was highest at academic facilities (40%). Privately insured patients were more likely to get the test compared to uninsured (45 versus 34%, p < 0.0001). Those in the highest income quartile were more likely to be tested (p < 0.001). CONCLUSIONS: ODX is under-utilized, with racial and socio-economic factors influencing testing. Further studies are necessary to identify ways to remove disparities and increase testing when appropriate.
BACKGROUND: Oncotype DX (ODX) is a multi-gene tumor assay for breast cancerpatients. Our objective is to assess whether eligible ODXpatients received the test and whether recommendations were followed based on respective risk. METHODS: We retrospectively analyzed testing in patients deemed eligible for ODX using the National Cancer Data Base. RESULTS: A total of 158,235 patients met ODX eligibility criteria. Sixty-four percent of eligible patients did not receive the test. Non-testing rose with age. White patients were more likely to be tested (56%) versus black patients (46%, p < 0.0001). Testing was highest at academic facilities (40%). Privately insured patients were more likely to get the test compared to uninsured (45 versus 34%, p < 0.0001). Those in the highest income quartile were more likely to be tested (p < 0.001). CONCLUSIONS:ODX is under-utilized, with racial and socio-economic factors influencing testing. Further studies are necessary to identify ways to remove disparities and increase testing when appropriate.
Authors: Austin D Williams; Kate R Pawloski; Hannah Y Wen; Varadan Sevilimedu; Donna Thompson; Monica Morrow; Mahmoud El-Tamer Journal: Breast Cancer Res Treat Date: 2022-10-21 Impact factor: 4.624
Authors: Seho Park; Yunan Han; Ying Liu; Adetunji T Toriola; Lindsay L Peterson; Graham A Colditz; Seung Il Kim; Young Up Cho; Byeong-Woo Park; Yikyung Park Journal: Breast Cancer Res Date: 2019-10-16 Impact factor: 6.466
Authors: Danielle Riley; Mary Charlton; Elizabeth A Chrischilles; Ingrid M Lizarraga; Sneha Phadke; Brian J Smith; Adam Skibbe; Charles F Lynch Journal: Breast J Date: 2022-08-30 Impact factor: 2.269
Authors: Nicholas Acuna; Jesse J Plascak; Jennifer Tsui; Antoinette M Stroup; Adana A M Llanos Journal: Int J Environ Res Public Health Date: 2021-05-12 Impact factor: 3.390